Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
2.
Clinics ; 70(9): 632-637, Sept. 2015. tab, ilus
Article in English | LILACS | ID: lil-759286

ABSTRACT

OBJECTIVE:To quantify the collagen fibers in the lacrimal gland of female mice with hyperprolactinemia.METHODS:Forty adult female mice were randomly divided into two groups with 20 animals each: nonpregnant control (CTR1, control group, 0.2 mL of saline solution) and nonpregnant experimental (HPRL1, experimental group, 200 µg/day metoclopramide). Treatments lasted for 50 consecutive days. On day 50, 10 females from each group (control and experimental) were euthanized in the proestrus phase; then, the blood was collected and the lacrimal glands were removed. Thereafter, the remaining females were placed with the mates and continued to receive treatment with saline solution or metoclopramide. On the 6th post-coital day, 10 pregnant females from the control group (CTR2) and 10 pregnant females from the experimental group (HPRL2) were euthanized, after which blood was collected and the lacrimal glands removed. The lacrimal glands were processed for morphological analyses and collagen quantification, and prolactin and sex steroid levels were measured in the blood samples. Data were statistically analyzed using an unpaired Student t test (p<0.05).RESULTS:Morphological analysis revealed greater structural tissue disorganization of the lacrimal glands in the metoclopramide-treated groups. The total collagen content was significantly higher in the HPRL1 group than in the CTR1 group (p<0.05), whereas the difference between the CTR2 and HPRL2 groups was not significant.CONCLUSION:Our data suggest an impairment in the functioning of the lacrimal gland as a consequence of increased prolactin levels and decreased serum levels of estrogen and progesterone.


Subject(s)
Animals , Female , Mice , Pregnancy , Collagen/drug effects , Hyperprolactinemia/chemically induced , Lacrimal Apparatus/drug effects , Collagen/analysis , Estradiol/blood , Hyperprolactinemia/blood , Hyperprolactinemia/pathology , Lacrimal Apparatus/pathology , Metoclopramide , Proestrus/blood , Progesterone/blood , Prolactin/blood , Radioimmunoassay , Random Allocation
3.
Rev. bras. ginecol. obstet ; 31(8): 385-390, ago. 2009. ilus, tab
Article in Portuguese | LILACS | ID: lil-528536

ABSTRACT

OBJETIVO: avaliar o efeito da hiperprolactinemia induzida pela metoclopramida sobre o endométrio e miométrio de camundongos fêmeas na fase de proestro. MÉTODOS: 24 camundongos fêmeas foram divididas aleatoriamente em dois grupos: GCtr/controle e GExp/tratadas com metoclopramida (6,7 µg/g por dia). Após 50 dias, os animais foram sacrificados na fase de proestro, e o sangue foi coletado para determinação dos níveis de estradiol, progesterona e prolactina. Os cornos uterinos foram removidos e fixados em formol a 10 por cento; foram, então, processados para inclusão em parafina. Cortes de 4 µm foram corados pela hematoxilina-eosina (H/E). Na análise morfológica, foi utilizado microscópio de luz, da marca Carl Zeiss, com objetivas variando de 4 a 400 X, para caracterização de cada corte histológico. Na análise morfométrica, foi avaliada a espessura do epitélio superficial, da lâmina própria e do miométrio, com auxílio de um analisador de imagem (AxionVision, Carl Zeiss) acoplado ao microscópio de luz (Carl Zeiss). A análise estatística foi realizada pela ANOVA seguida pelo teste Wilcoxon. O valor de p foi considerado significante quando < 0,05. RESULTADOS: os achados mostraram aumento dos níveis séricos de prolactina (295,6±38,0 ng/mL) e redução significante dos de progesterona (11,3±0,9 ng/mL) no GExp em comparação ao GCtr (45,5±5,2 ng/mL e 18,2±1,6 ng/mL, respectivamente) (p<0,001). Com relação aos níveis séricos de estradiol, não foram obtidas diferenças significantes entre os grupos (GExp=119,1±12,3 pg/mL e o GCtr=122,7±8,4 pg/mL, p=0,418). O estudo morfológico mostrou que o útero do GExp apresentou endométrio com epitélio superficial e lâmina própria mais desenvolvida quando comparado ao GCtr, o mesmo ocorrendo no miométrio. Os valores morfométricos das espessuras do epitélio luminal (8,0±1,1 µm) e do endométrio (116,2±21,1x10² µm) do GCtr foram inferiores ao GExp (10,2±0,8 µm e 163,2±23,3x10² µm com p<0,05) respectivamente. Já os dados ...


PURPOSE: to evaluate the effect of hyperprolactinemia induced by metoclopramide on the endometrium and myometrium of female mice in the proestrus phase. METHODS: 24 female mice were randomly divided in two groups: CtrG/control and ExpG/treated with metoclopramide (6.7 mg/g daily). After 50 days, the animals were sacrificed in the proestrus phase, and the blood was collected to determine the levels of estradiol, progesterone and prolactin. The uterine horns were removed, fixed in 10 percent formaldehyde and processed before being included in paraffin. Slices of 4 µm were stained by hematoxylin and eosin (H/E). In the morphological analysis, a Carl Zeiss light microscope, with objectives varying from 4 to 400 X was used for each histological slice characterization. In the morphometrical analysis, the superficial epithelium, the lamina propria and the myometrium thickness were evaluated, with the help of an image analyzer (AxionVision - Carl Zeiss) attached to the light microscope (Carl Zeiss). The statistical analysis was done by ANOVA, followed by the Wilcoxon test. P-value was considered as significant, when <0.05. RESULTS: our findings have shown an increase in the seric levels of prolactin (295.6±38.0 ng/mL) and significant decrease in the progesterone levels (11.3±0.9 ng/mL) in the ExpG, as compared to the CtrG (45.5±5.2 ng/mL and 18.2±1.6 ng/mL, respectively; p<0.001). Concerning the seric level of estradiol, significant differences between the groups were not obtained (ExpG=119.1±12.3 pg/mL and CtrG=122.7±8.4 pg/mL; p=0.418). The morphological study has shown that the uterus from the ExpG presented the endometrium with more developed superficial epithelium and lamina propria, as compared to the CtrG, the same happening with the myometrium. The thickness morphometrical values of the luminal epithelium (8.0±1.1 µm) and endometrium (116.2±21.1x10² µm) from the CtrG were lower than the ones from the ExpG (10.2±0.8 µm and 163.2±23.3x10² ...


Subject(s)
Animals , Female , Mice , Hyperprolactinemia/pathology , Proestrus , Uterus/pathology , Hyperprolactinemia/blood
4.
Arq. bras. oftalmol ; 69(5): 645-649, set.-out. 2006. ilus, tab
Article in Portuguese, English | LILACS | ID: lil-439306

ABSTRACT

OBJETIVO: Avaliar as alterações morfológicas promovidas pela hiperprolactinemia induzida pela metoclopramida na córnea de camundongas durante a fase de proestro e na gestação. MÉTODOS: Quarenta camundongas adultas foram divididas, aleatoriamente, em dois grupos, a saber: controle (CTR1) e metoclopramida (MET1). Após 50 dias metade dos animais de cada grupo foram sacrificados. O restante dos animais foi acasalado, constituindo dois grupos: controle prenhe (CTR2) e o metoclopramida prenhe (MET2), que foi sacrificado no 6° dia de gestação. Após decapitação dos animais coletou-se sangue para dosagens de estradiol, progesterona e prolactina, em seguida removidos os globos oculares para estudo histomorfométrico da córnea. RESULTADOS: As espessuras do epitélio, estroma, endotélio e a espessura total das córneas dos grupos experimentais: MET1 e MET2 mostraram-se mais espessados quando comparados com os grupos controles: CTR1 e CTR2, respectivamente. Houve redução dos níveis hormonais do estrogênio e da progesterona nos animais que receberam metoclopramida em comparação com os respectivos controles (CTR1: estradiol = 156,6±42,2 pg/ml; progesterona = 39,4±5,1 ng/ml; prolactina = 130,4±26,2 ng/ml; MET1: estradiol = 108,0±33,1 pg/ml; progesterona = 28,0±6,4 ng/ml; prolactina = 551,5± 23,3 ng/ml; CTR2: estradiol = 354,0±56,0 pg/ml; progesterona = 251,0± 56,0 ng/ml; prolactina = 423,2±28,1 ng/ml; MET2: estradiol = 293,0± 43,0 pg/ml; progesterona = 184,0±33,0 ng/ml; prolactina = 823,1±51,1 ng/ml). CONCLUSÃO: A hiperprolactinemia induzida pela metoclopramida produziu espessamento da córnea, sobretudo, em camundongas prenhes. Possivelmente este efeito está relacionado com a redução da produção hormonal de estrogênio e de progesterona.


PURPOSE: To evaluate the morphological changes in murine cornea upon metoclopramide-induced hyperprolactinemia during the proestrous phase or pregnancy. METHODS: Forty adult mice were divided into two groups: (control) CTR1 and (treated with metoclopramide (MET1). After fifty days, half of the mice were sacrificed. The remaining animals were mated, and then labeled as pregnant controls (CTR2). Part of these animals were treated with metoclopramide and constituted the metoclopramide-treated pregnant (MET2) group. The groups CTR2 and MET2 were sacrificed on the 6th day of pregnancy. The hormonal levels were assessed by chemioluminescence and radioimmunoassay methods and the cornea was removed for the histomorphometric study. RESULTS: The epithelial, stromal, endothelial and total thickness in the experimental group was: MET1 and MET2 were higher than one in the control group: CTR1 and CTR2. There was a significant reduction of the hormonal level in the animals that received metoclopramide as compared to controls (CTR1: estradiol = 156.6±42.2 pg/ml; progesterone = 39.4±5.1 ng/ml; prolactin = 130.4±26.2 ng/ml; MET1: estradiol = 108.0±33.1 pg/ml; progesterone = 28.0±6.4 ng/ml; prolactin = 551.5±23.3 ng/ml; CTR2: estradiol = 354.0±56.0 pg/ml; progesterone = 251.0±56.0 ng/ml; prolactin = 423.2±28.1 ng/ml; MET2: estradiol = 293.0±43.0 pg/ml; progesterone = 184.0±33.0 ng/ml; prolactin = 823.1±51.1 ng/ml). CONCLUSION: The metoclopramide-induced hyperprolactinemia may increase corneal layers, mainly in pregnant mice. Possibly, this effect is related to reduction in estrogen and progesterone production.


Subject(s)
Animals , Female , Pregnancy , Mice , Cornea/drug effects , Dopamine Antagonists/toxicity , Gonadal Hormones/blood , Hyperprolactinemia/pathology , Metoclopramide/toxicity , Proestrus/drug effects , Aqueous Humor , Cornea/pathology , Disease Models, Animal , Estradiol/blood , Histocytochemistry , Hyperprolactinemia/chemically induced , Image Processing, Computer-Assisted , Pregnancy, Animal , Progesterone/blood , Prolactin/blood
5.
Arch. Clin. Psychiatry (Impr.) ; 33(2): 68-73, 2006. tab
Article in Portuguese | LILACS, SES-SP | ID: lil-435529

ABSTRACT

A hiperprolactinemia é o distúrbio endócrino mais freqüente do eixo hipotálamo-hipofisário, observado em mulheres na idade reprodutiva. Caracteriza-se pela elevação consistente dos valores plasmáticos de prolactina. A regulação da produção da prolactina dá-se por meio da ação inibitória de um neurotransmissor, a dopamina. As manifestações clínicas são distúrbios do ciclo menstrual, amenorréia, galactorréia, infertilidade e diminuição da libido. Entretanto, sintomas psicológicos, especialmente ansiedade e depressão, têm sido associados à hiperprolactinemia. Contudo, há poucos estudos clínicos publicados sobre o tema. O papel da prolactina na patogênese dos distúrbios psiquiátricos pode refletir ação direta sobre o sistema nervoso central, efeito indireto por meio dos hormônios gonadais ou constituir fatores independentes, resultantes da depleção de dopamina. Assim, detectada a prevalência de distúrbios psiquiátricos em pacientes com hiperprolactinemia, conclui-se pela necessidade de maior número de pesquisas que investiguem as bases da possível inter-relação entre os estados hiperprolactinêmicos e o psiquismo.


Hyperprolactinemia is the most frequent endocrine disorder of the hypothalamus-hypophysis axis observed in women of reproductive age. It is characterized by elevated serum prolactin levels. Prolactin production is regulated by the inhibitory action of a neurotransmitter, dopamine. Clinical manifestations include irregular menstrual cycle, amenorrhea, galactorrhea, infertility and libido decrease, but psychological symptoms, especially anxiety and depression, have also been associated with hyperprolactinemia. Nonetheless, few studies about this condition are available. In the pathogenesis of psychiatric disorders, prolactin may have either a direct action on the central nerve system or an indirect effect via gonadal hormones or function as independent factors as a result of dopamine depletion. Thus, since the prevalence of psychiatric disorders in patients with hyperprolactinemia was detected, it was concluded that further studies are necessary to investigate the basis of a potential relationship between both hyperprolactinemic and psychiatric conditions.


Subject(s)
Hyperprolactinemia/psychology , Dopamine/adverse effects , Hyperprolactinemia/pathology , Hyperprolactinemia/therapy
6.
Rev. méd. Chile ; 129(3): 295-8, mar. 2001. ilus
Article in Spanish | LILACS | ID: lil-286865

ABSTRACT

The association of hyperprolactinemia over 100 ng/ml and a pituitary adenoma is usually diagnostic of prolactinoma. However type 3 pituitary adenomas can occur with similar serum prolactin values. We report a 31 years old woman that consulted due to headache and photopsiae. She had a serum prolactin level of 148 ng/ml and imaging studies showed a solid tumor that occupied the selar region and most of the left temporal fossa. The tumor was partially resected and the patient recovered her lost visual field. Light microscopy showed an acidophilic and in part chromophobe adenoma. Immuno-histochemistry was positive for prolactin and growth hormone. Electron microscopy disclosed features of a silent type 3 adenoma such as big cells with cytoplasmic prolongations, pleomorphic nuclei and a greatly developed rough endoplasmic reticulum


Subject(s)
Humans , Female , Adult , Pituitary Neoplasms/ultrastructure , Hyperprolactinemia/pathology , Adenoma/ultrastructure , Prolactin/blood , Visual Fields , Diagnosis, Differential
7.
Ginecol. & obstet ; 45(2): 86-90, abr. 1999. tab
Article in Spanish | LILACS, LIPECS | ID: lil-270758

ABSTRACT

Objetivos: identificar las características de pacientes con infertilidad e hiperprolactinemia (HPRL). Método: Se revisó 464 historias clínicas de 39 mujeres del Servicio de Infertilidad del Hospital Arzobispo Loayza (HAL); seleccionándose las que tenían por lo menos 2 dosajes de prolactina (PRL) sérica mayores de 25 ng/ml, edades entre 15 y 42 años, tiempo de infertilidad mayor 1 año y vida sexual activa. Resultados: Las pacientes con HPRL representan el 8,4 de mujeres infértiles del HAL. Del ellos, 56,4 por ciento tenía PRL entre 26 y 50 ng/mL; edad promedio de 33,1 años y tiempo de enfermedad de 5,4 años. Los antecedentes más relevantes fueron: aborto (48,7 por ciento), galactorrea 35,9 por ciento), trastornos menstruales (25,6 por ciento), relaciones sexuales insatisfactorias (23,1 por ciento) y ejercicio físico (23,1 por ciento). Los hallazgos clínicos más importantes fueron: galactorrea (46,2 por ciento), índice de masa corporal mayor 25 (44,8 por ciento) y fase lútea inadecuada (43,6 por ciento). Los diagnósticos etiológicos más frecuentes fueron: HPRL idiopática (53,8 por ciento) y fisiológica (20,5 por ciento). Las pacientes con microadenoma de hipófisis tuvieron niveles de PRL significativamente mayores que mujeres con otras etiologías de HPRL (p menor 0,05). Conclusiones: La prevalencia de HPRL en pacientes infértiles fue menor de lo esperado. Las pacientes con HPRL acudieron tarde por ayuda médica.


Subject(s)
Humans , Female , Adolescent , Adult , Prolactin , Hyperprolactinemia/diagnosis , Hyperprolactinemia/etiology , Hyperprolactinemia/pathology , Infertility , Retrospective Studies , Hospitals, State , Epidemiology, Descriptive
8.
Bulletin of Alexandria Faculty of Medicine. 1991; 27 (3): 747-51
in English | IMEMR | ID: emr-19346

ABSTRACT

The study included 20 females with hyperprolactinemia of different causes. They were subjected to careful history taking and physical examination. The basal serum prolactin and thyroid stimulating hormone [TSH] were assayed. Fundus examinations, plain X- ray skull and cat scan were done in some cases. Ten cases were given 7.5 mg oral bromocriptine daily for three months. The other ten cases were given long acting bromocriptine in repeated injections [LAR] in a dose of 50 mg monthly for three months. There were no significant differences in the efficacy of parlodel tablets and injections in suppressing serum prolactin. Also, no significant difference in the clinical efficacy was found except a more significant effect for the injections in galactorrhea. The number of cases with side effects was equal but its duration was shorter with the injections. Parlodel LAR injections can be repeatedly used without any side effects especially in patients who cannot tolerate the gastrointestinal side effects of the oral tablets and in galactorrhea cases


Subject(s)
Prolactin , Hyperprolactinemia/pathology
SELECTION OF CITATIONS
SEARCH DETAIL